Table 1.
The demographic characteristics and medication use of patients at baseline
| Clinical characteristics | Values |
|---|---|
| Age (years) | 58.4 ± 13.8 |
| Female/male | 49/15 |
| Disease duration (years) | 13.1 ± 11.8 |
| BMI | 21.8 ± 4.0 |
| Smoking, n (%) | 8 (12.7) |
| Hypertension, n (%) | 23 (36.5) |
| Diabetes, n (%) | 6 (9.7) |
| Total cholesterol (mg/dL) | 197.4 ± 39.3 |
| LDL (mg/dL) | 114.9 ± 37.5 |
| HDL (mg/dL) | 59.6 ± 15.0 |
| Triglycerides (mg/dL) | 108.2 ± 46.0 |
| PSL use, n (%) | 31 (48.4) |
| PSL dose (mg/day) | 2.0 ± 2.3 |
| MTX use, n (%) | 45 (70.3) |
| MTX dose (mg/week) | 5.7 ± 3.5 |
| Biologics (IFX/ETN/ADA/GLM/TCZ/ABT) | 18/14/16/2/13/1 |
The data are expressed as the mean ± standard deviation
BMI body mass index; LDL low-density lipoprotein cholesterol; HDL high-density lipoprotein cholesterol; PSL prednisolone; MTX methotrexate; IFX infliximab; ETN etanercept; ADA adalimumab; GLM golimumab; TCZ tocilizumab; ABT abatacept